Sermorelin vs. HGH: What Is the Difference?

Sermorelin and HGH are not two versions of the same drug. HGH (somatropin) is lab-made growth hormone itself, injected directly. Sermorelin is a 29 amino acid copy of the active end of growth hormone-releasing hormone (GHRH), the brain signal that tells your pituitary gland to release its own growth hormone. HGH is FDA approved for specific diagnoses, and federal law makes it a crime to distribute it for anti-aging or bodybuilding. Sermorelin was FDA approved as Geref, mainly for children, and was discontinued in 2008. As of September 2026 no FDA-approved sermorelin product exists in the US, what is available comes from compounding pharmacies or from third-party-tested peptide suppliers, and the studies in healthy adults are small and short.

Two different drugs that act at two different points

Growth hormone (GH) is a protein made by the pituitary, a pea-sized gland at the base of your brain. It does not pour out steadily. It is released in bursts, and the biggest bursts happen at night during sleep. Once in the blood, GH travels to the liver and other tissues, where it triggers production of insulin-like growth factor 1 (IGF-1), the hormone that carries out much of GH's effect on muscle, bone, and fat.

Three signals control those bursts, according to the NIH-hosted endocrinology reference Endotext. GHRH, made in the hypothalamus (the brain region just above the pituitary), is the main "go" signal. Somatostatin, also from the hypothalamus, is the "stop" signal. Ghrelin, a hormone made mostly in the stomach, is a second "go" signal that works through a separate receptor. Rising GH and IGF-1 feed back on the brain and pituitary to turn the system down. It behaves like a thermostat, not a faucet.

What HGH is

Prescription HGH is somatropin, a recombinant copy (made by bacteria engineered to produce it, not taken from human tissue) of the 191 amino acid hormone your pituitary makes. When you inject it, you are adding the finished hormone to your bloodstream. It works whether or not your pituitary is functioning, which is exactly why it is the treatment for people whose pituitary cannot make enough.

The pharmacology section of the Norditropin label, one of several FDA-approved somatropin brands, shows what an injection looks like in the blood. After a dose under the skin, GH levels climb to a peak roughly 3 to 5 hours later, and the apparent half-life (the time for the blood level to fall by half) is about 7 to 10 hours because the drug absorbs slowly from the injection site. That is one broad, hours-long swell of hormone, not a series of bursts, and your body's feedback system has no way to shut it off.

What sermorelin is

Natural GHRH is a longer peptide, but only its first 29 amino acids are needed for full activity. Sermorelin is that 29 amino acid fragment, written in the literature as GHRH (1-29) NH2. A 1999 review in the journal BioDrugs described it as the shortest synthetic peptide with the full biological activity of GHRH.

Sermorelin does not contain growth hormone and does not act on muscle or fat directly. It binds the GHRH receptor on pituitary cells and prompts them to release the GH they have already made. In a 1997 trial in adults aged 55 to 71 that used a near-identical analog (one amino acid swapped), an evening injection triggered GH release within 10 minutes, and the burst lasted about 2 hours. Then levels fell back.

That design has two consequences. First, sermorelin can only work if your pituitary is healthy enough to respond. Second, the size of the response is capped by your own biology: somatostatin and IGF-1 feedback still apply. Endotext summarizes the difference this way: treatment with GHRH produces a pulsatile GH response, not a prolonged elevation, and preserves negative feedback. Whether that more natural pattern translates into better long-term safety has been argued on theory but has not been tested in long trials.

Pulses, feedback, and why they matter

Much of the case made for sermorelin over HGH rests on physiology, so it is worth being precise about what is known and what is inferred.

What happens to growth hormone as you age

GH output falls steadily through adult life. Endotext puts the decline at roughly 15 percent per decade after your twenties, driven mainly by smaller nighttime pulses, with little change in how often pulses occur. IGF-1 falls along with it. This is sometimes called the somatopause.

An important detail came from a 1992 National Institute on Aging study by Corpas and colleagues. When healthy men with an average age of 68 were given an intravenous test dose of GHRH, their pituitaries released as much GH as those of men with an average age of 26. The older pituitary still had the hormone. What had changed was the signal reaching it. That finding is the scientific rationale for giving a GHRH analog instead of GH itself.

The feedback argument, stated fairly

With injected HGH, the dose you take is the dose you get. If it is too high for you, IGF-1 climbs above the normal range and side effects follow. With sermorelin, the pituitary still answers to somatostatin and IGF-1, so in principle the body can blunt an excessive response. A 2018 review of growth hormone secretagogues in Sexual Medicine Reviews made the same point: these drugs promote pulsatile GH release that is subject to negative feedback, which may prevent the very high GH levels seen with overdosed HGH.

That is a reasonable mechanism, and the side effect pattern in small trials is consistent with it. It is still an inference. The same 2018 review concluded that few long-term, rigorously controlled studies exist and that long-term safety, including cancer incidence and mortality, still needs to be evaluated. A 2006 editorial often quoted in sermorelin marketing, by Walker in Clinical Interventions in Aging, argues that sermorelin preserves the pituitary and slows hormonal aging. It is an opinion piece that presents no trial data, and it announces that the author's own society would be supplying sermorelin free to practitioners willing to study it, so it should be read as advocacy, not evidence.

The ceiling effect cuts both ways

Feedback limits risk, and it also limits effect. In children with GH deficiency, the 1999 BioDrugs review noted that height gains with sermorelin given at 30 mcg per kg per day by infusion or divided doses were smaller than those seen with once-daily somatropin at the same weight-based dose, and that sermorelin worked in some children, not all. If you are expecting sermorelin to reproduce the body composition changes reported in HGH trials, the available data do not support that expectation.

How sermorelin was approved as Geref, and why it left the market

Sermorelin is unusual among the peptides promoted for wellness because it was once a fully FDA-approved drug. The history is laid out in a 2013 Federal Register notice from the FDA.

• December 28, 1990: FDA approved Geref (sermorelin acetate) injection, 0.05 mg per ampule, as a diagnostic agent for evaluating the ability of the pituitary to secrete growth hormone.
• September 26, 1997: FDA approved Geref in 0.5 mg and 1.0 mg vials for the treatment of idiopathic growth hormone deficiency in children with growth failure. Idiopathic means no structural cause was found.
• July 11, 2008: the manufacturer, EMD Serono, notified the FDA that it was discontinuing the diagnostic ampules.
• December 2, 2008: the manufacturer notified the FDA that it was discontinuing the treatment vials and asked for that approval to be withdrawn.
• June 18, 2009: FDA withdrew approval of both applications at the company's request.
• March 4, 2013: FDA published its formal determination that Geref was not withdrawn from sale for reasons of safety or effectiveness, which leaves the door open for a generic application in the future.

Two points are easy to miss. Geref was never approved for adults as a treatment, and never for aging, weight loss, sleep, or athletic recovery. Its treatment approval was for children with a diagnosed deficiency. And the evidence behind that approval was modest by modern standards.

The pediatric trial behind the approval

The main study, published by Thorner and the Geref International Study Group in 1996, was an open-label trial, meaning there was no placebo group and everyone knew what they were receiving. It enrolled 110 previously untreated children with GH deficiency, who received 30 mcg per kg of sermorelin under the skin at bedtime for up to a year. Among the 86 children who could be analyzed, average growth rate rose from 4.1 cm per year at baseline to 8.0 cm per year at 6 months and 7.2 cm per year at 12 months. About 74 percent were judged good responders at 6 months. Fasting glucose did not change, and IGF-1 did not rise excessively.

What the FDA's 2013 finding does and does not mean

The "not withdrawn for safety or effectiveness" determination is a regulatory finding about why a product left the market. It is not an endorsement of any sermorelin sold today, compounded or otherwise, and it is not evidence that sermorelin works for uses that were never studied for approval. No generic sermorelin product has taken Geref's place, so as of September 2026 there is no FDA-approved sermorelin product sold in the United States.

Where sermorelin stands with the FDA today

As of September 2026, no FDA-approved sermorelin product is sold in the US. What is available comes by one of two routes: compounding pharmacies and outsourcing facilities, which prepare it from bulk ingredient on a prescription, or peptide suppliers that sell third-party-tested product with a certificate of analysis, which a physician then reconstitutes and dispenses. Neither route is FDA reviewed. The FDA is direct about what that means for compounded drugs: they are not FDA approved, and the agency does not verify their safety, effectiveness, or quality before they are marketed. Supplier-sourced peptide is not FDA verified either; its quality rests on the independent laboratory testing behind each batch rather than on pharmacy practice standards.

Compounding status

For the compounding route, federal law limits which bulk ingredients compounders may use. Under section 503A of the Food, Drug, and Cosmetic Act, which covers traditional pharmacies filling individual prescriptions, a bulk substance must have a USP or National Formulary monograph, or be a component of an FDA-approved drug, or appear on the FDA's 503A bulks list. Under section 503B, which covers larger outsourcing facilities, the FDA keeps interim category lists while it evaluates nominated substances.

On the FDA's 503B interim list (the posted version is dated March 21, 2025), sermorelin acetate appears in Category 1, the group of substances under evaluation, and it is flagged there as a component of an FDA-approved drug. Sermorelin does not appear in any category of the FDA's 503A nominated-substances list, including Category 2, the group the agency says raises significant safety concerns.

You may have seen news about the FDA and peptides in 2026. In April 2026 the agency announced it was removing a group of peptides from 503A Category 2 after their nominations were withdrawn, and it set Pharmacy Compounding Advisory Committee meetings to consider them. Sermorelin was not part of that action: it does not appear among the Category 2 substances or the withdrawn nominations that the FDA lists. Its history as a formerly approved drug sets it apart from most wellness peptides, including ipamorelin, which is covered in a separate guide.

What this means for you in practice

Available from a compounding pharmacy is not the same as quality-checked, and neither is a certificate of analysis on its own. The FDA documents reviewed for this article also do not spell out which of the compounding pathways above applies to sermorelin now that Geref's approval has been withdrawn, so this guide does not assert one. Along the compounding route, potency, sterility, and purity depend on the individual pharmacy; the FDA notes that poor compounding practices can lead to contamination or to products with too much or too little active ingredient. Along the supplier route, they depend on whether each batch was actually tested by an independent laboratory and whether the physician dispensing it has that report in hand. Sermorelin sold online without a prescription, or labeled "for research use only", sits outside both of these and has no quality oversight at all.

Rx2BFIT sources its sermorelin from a supplier whose batches are tested by an independent laboratory for identity and purity, keeps the certificate of analysis on file, and reconstitutes it in the office under Dr. Patel's supervision. It is not an FDA-approved medication, and that, along with the known risks and the limits of the evidence, is reviewed with every patient before starting.

Status in sport

If you compete in a tested sport, both drugs are off the table. The World Anti-Doping Agency's 2026 Prohibited List, in effect from January 1, 2026, bans growth hormone under section S2.2.3 and names sermorelin under S2.2.4 as a prohibited GHRH analog, alongside CJC-1295 and tesamorelin. Substances in section S2 are prohibited at all times, in and out of competition.

Why HGH prescribing is legally restricted in the United States

HGH has a legal status that almost no other non-controlled prescription drug shares. For most medications, a doctor may prescribe off label, meaning for a use the FDA has not approved, when they judge it appropriate. HGH is a statutory exception.

Under 21 U.S.C. 333(e), anyone who knowingly distributes human growth hormone, or possesses it with intent to distribute, for any use in humans other than treatment of a disease or recognized medical condition where that use has been authorized by the Secretary of Health and Human Services, and pursuant to a physician's order, commits a federal offense. The penalty is up to 5 years in prison, fines, or both, rising to up to 10 years if the offense involves someone under 18. The Drug Enforcement Administration is authorized to investigate.

What HGH is approved for

The FDA's import alert on HGH lists the main authorized uses, noting there are others. In children, these include growth failure from GH deficiency, chronic kidney disease, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, SHOX deficiency, being born small for gestational age without catch-up growth, and idiopathic short stature. In adults, the alert names adult-onset or childhood-onset GH deficiency and short bowel syndrome in patients receiving specialized nutritional support.

The same FDA document states that the Secretary has not authorized any HGH use for anti-aging, bodybuilding, or athletic enhancement, and that HGH marketed as a "fountain of youth" is not approved for those purposes. Adult GH deficiency is a specific diagnosis, not a description of normal aging. The Endocrine Society's clinical practice guideline says it usually has to be confirmed with stimulation testing, in which a drug is given to provoke GH release and the response is measured, unless there is a proven structural or genetic cause dating from childhood.

How commentators read the law for sermorelin

The statute defines human growth hormone as somatrem, somatropin, or an analogue of either. Sermorelin is an analog of GHRH, a different hormone, and commentators including the 2006 Walker editorial read the HGH distribution provision as not applying to it. That is a legal interpretation by commentators, not a court ruling or an FDA statement, and none was located for this article. It is the reasoning clinics rely on when they offer sermorelin, and not HGH, for age-related complaints.

Keep that in perspective. That reading of the law explains why sermorelin is offered. It says nothing about whether sermorelin works for the reason you are considering it. That question can only be answered by the clinical evidence.

What the evidence shows in adults

There is far more adult research on HGH than on sermorelin, and the HGH research is mostly sobering. Here is each body of evidence, with study sizes, because the sizes matter.

HGH in adults with true growth hormone deficiency

In adults whose pituitary has been damaged by a tumor, surgery, radiation, or another cause, GH replacement is established care. The Endocrine Society guideline concludes that GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life, that benefit is most likely in people with more severe deficiency, and that doses should be individualized. This is the population the drug was approved for, supported by randomized, placebo-controlled trials.

HGH in healthy older adults

The modern interest in GH for aging began with a 1990 New England Journal of Medicine study by Rudman and colleagues. It involved 21 healthy men aged 61 to 81 with low IGF-1. Twelve received HGH three times a week for 6 months, and 9 received nothing. The treated men gained 8.8 percent in lean body mass, lost 14.4 percent of fat mass, and gained 1.6 percent in lumbar spine bone density. The study was small, was not blinded, and did not measure strength or function. It was widely over-interpreted.

Better trials followed. In a 2002 JAMA trial by Blackman and colleagues, 131 healthy adults aged 65 to 88 were randomized to GH, sex steroids, both, or placebo for 26 weeks. GH alone raised lean mass by 1.0 kg in women and 3.1 kg in men and reduced fat mass. Strength did not improve significantly with GH alone in either sex. Side effects were frequent: swelling in 39 percent of women on GH versus none on placebo, joint pain in 41 percent of men on GH versus none, and diabetes or glucose intolerance in 18 GH-treated men versus 7 men not receiving GH. The authors concluded that GH in older adults should be confined to controlled studies.

A 2007 systematic review in Annals of Internal Medicine by Liu and colleagues pooled 31 articles covering 18 study populations, with 220 GH-treated participants who completed their studies. Average treatment lasted 27 weeks. Fat mass fell by 2.1 kg and lean mass rose by 2.1 kg, while body weight did not change. Bone density and most cholesterol measures did not improve. Treated participants were significantly more likely to develop soft tissue swelling, joint pain, carpal tunnel syndrome, and breast enlargement in men, and somewhat more likely to develop diabetes or impaired fasting glucose. The review's conclusion was that GH cannot be recommended as an anti-aging therapy.

Sermorelin and GHRH in older adults

Now the sermorelin side. No trial has tested sermorelin in thousands, or even hundreds, of healthy adults. The published human evidence consists of a handful of small studies, mostly from the 1990s, in adults roughly 55 to 76 years old.

Endotext also summarizes a 6 month University of Washington trial of bedtime sermorelin, alone or with exercise training, in which IGF-1 rose by about 35 percent, lean mass increased, and fat decreased, but strength and aerobic fitness did not improve. That figure comes from review articles written by the trial's own investigators, including a 2008 review in Clinical Interventions in Aging. A full peer-reviewed report of the body composition results could not be located for this article, so treat the number as approximate. Endotext also notes that, although poor deep sleep and low GH travel together in aging, most studies giving GH or GHRH to older adults did not improve slow wave sleep.

Put together, these studies show that sermorelin and its close analog reliably do what they are designed to do in the short term: they raise your own GH output and, at adequate doses, nudge IGF-1 upward. Changes in body composition are small and inconsistent, and appeared mainly in men. No study has shown improvements in strength, fitness, fracture risk, heart disease, or lifespan. None lasted longer than about 6 months. For a closer look at the time course in these studies, see how long sermorelin takes to work.

No head-to-head trial exists

No published randomized trial has compared sermorelin with HGH in adults for any outcome. Every claim that one is "as effective as" or "safer than" the other in adults is an indirect comparison across different studies, populations, and eras. The only semi-direct comparison comes from children with GH deficiency, where sermorelin produced less growth than somatropin.

Side effects and risks of each

HGH

HGH side effects are well characterized because the drug has decades of trial and surveillance data. In adults they are mostly dose related and driven by fluid retention. In a 6 month placebo-controlled trial in adults with GH deficiency, reported in the Norditropin label, the most common adverse reactions were:

The label's warnings go further. Somatropin can reduce insulin sensitivity, particularly at higher doses, so glucose should be monitored. Intracranial hypertension (raised pressure around the brain, causing headache, nausea, and vision changes) has been reported, usually within the first 8 weeks. It can unmask an underactive thyroid or adrenal insufficiency. Pancreatitis has been reported. Because GH and IGF-1 promote cell growth, the label warns of an increased risk of second tumors in childhood cancer survivors and calls for monitoring any preexisting tumor for progression.

Somatropin is contraindicated, meaning it must not be used, in people with active cancer, in acute critical illness after open heart or abdominal surgery, major trauma, or acute respiratory failure, in active proliferative or severe non-proliferative diabetic retinopathy, and in children whose growth plates have closed. The critical illness warning comes from two placebo-controlled intensive care trials involving 522 adults without GH deficiency, in which high-dose somatropin (5.3 to 8 mg per day) was associated with 42 percent mortality versus 19 percent on placebo. The label states plainly that somatropin is not indicated for adults who are not GH deficient.

On long-term safety, the largest dataset is the European SAGhE cohort: 24,232 people treated with GH in childhood, with more than 400,000 patient-years of follow-up. Among low-risk patients with isolated GH deficiency or idiopathic short stature, overall mortality was not significantly increased, and mortality was not related to GH dose. Deaths from circulatory and blood diseases were higher than expected across risk groups, and the authors called for continued surveillance. These data are from people treated as children for medical reasons. They do not tell you about decades of use in healthy adults.

Sermorelin

The side effect record for sermorelin is milder and much thinner. In the 1999 BioDrugs review of the pediatric and diagnostic data, the most commonly reported events were transient facial flushing and pain at the injection site, and repeated daily doses were described as well tolerated. In the year-long pediatric trial there were no adverse changes in blood chemistry, fasting glucose, or IGF-1.

In the adult studies, Corpas found no effect on fasting glucose, blood pressure, or routine blood tests over 14 days. Vittone reported no significant adverse effects over 6 weeks. Khorram, using the analog, reported a temporary rise in blood lipids that resolved by the end of the 16 week study. Endotext's summary is that side effects of GHRH treatment are similar in character to those of GH but milder and less frequent. The 2018 secretagogue review reached a similar conclusion for the class while flagging some concern about rising blood glucose from reduced insulin sensitivity.

The limits of that reassurance need to be stated just as plainly:

• The adult studies enrolled about 10 to 90 people each and lasted 2 weeks to 6 months. Rare side effects and slow-developing ones cannot be detected in studies that size.
• There are no long-term data on cancer risk, cardiovascular outcomes, or mortality with sermorelin in adults. Anything that raises GH and IGF-1 carries the same theoretical concern about promoting growth of an existing tumor, which is why active cancer is treated as a reason to avoid it.
• The old safety data come from a manufactured, FDA-approved product. Today's supply, whether compounded or supplier-sourced, is not FDA reviewed, which adds product quality as a separate variable.
• Doses and combinations used in wellness settings, such as pairing sermorelin with other GH-releasing peptides, have not been studied in the trials described here.

When to seek urgent care

If you are using either drug, get same-day medical attention for any of the following: a severe or persistent headache with nausea or changes in vision; swelling of the face, lips, or throat, hives, or trouble breathing after an injection; severe upper abdominal pain, especially with vomiting; or marked thirst and frequent urination, which can signal high blood sugar. Report new or worsening joint pain, hand numbness, or ankle swelling to your prescriber promptly, since these usually mean the GH effect is too strong for you.

Sermorelin vs. HGH at a glance

IGF-1 monitoring: what it is and why it is used

Because GH is released in bursts and cleared quickly, a single GH blood test tells you almost nothing. It may catch a peak or a trough. IGF-1 is far more stable through the day, so it serves as the practical yardstick of how much GH effect your body has been getting.

How IGF-1 is used with HGH

The somatropin label builds IGF-1 into dosing. For adults it describes starting low, around 0.2 mg per day (range 0.15 to 0.3 mg), and adjusting every 1 to 2 months according to clinical response and serum IGF-1. It instructs prescribers to lower the dose if side effects occur or if IGF-1 rises above the normal range for your age and sex. It also notes that older adults are more prone to side effects and may need lower doses, and that women taking oral estrogen may need higher ones. These are label facts for a supervised, diagnosed patient, not a guide for self-dosing.

How IGF-1 is used with sermorelin

There is no current FDA label for sermorelin, so there is no official monitoring schedule. In practice, prescribers borrow the HGH approach: a baseline IGF-1 before starting, a repeat after a period of treatment, and interpretation against the reference range for your age. The research supports two expectations. IGF-1 should rise modestly if the drug is working, as it did within 2 weeks in the Khorram study of a close analog and by roughly 35 percent in the 6 month sermorelin trial as summarized by its investigators. And it may not rise at all: Vittone's once-nightly regimen increased GH pulses without moving IGF-1.

A flat IGF-1 on sermorelin can mean the dose or timing is not producing enough GH, that the product is underpotent, or that something is blunting your response. Obesity, for example, is associated with lower GH secretion and a weaker response to GH-releasing drugs, according to Endotext. An IGF-1 above the age-adjusted range is a signal to reduce or stop, for the same reasons it is with HGH.

Other tests your prescriber may order

Because GH opposes insulin, a fasting glucose or hemoglobin A1c (a 3 month average of blood sugar) is a sensible companion test, particularly if you have prediabetes. The somatropin label also calls for periodic thyroid monitoring, since GH treatment can unmask hypothyroidism. If your baseline IGF-1 is very low for your age, or you have a history of pituitary disease, head trauma, or cranial radiation, the appropriate next step is a formal evaluation for GH deficiency by an endocrinologist, not an empirical trial of a secretagogue.

Who each one is for, and who should avoid both

When HGH is the right drug

If you have confirmed adult GH deficiency, HGH is the evidence-based, FDA-approved treatment, and sermorelin is not a substitute. A damaged pituitary may not be able to respond to GHRH at all. The 1999 review also noted the reverse diagnostic problem: a normal GH response to sermorelin cannot rule out deficiency caused by a hypothalamic defect, so other stimulation tests are needed.

Where sermorelin fits

Sermorelin is prescribed off label to adults with age-related decline in GH and IGF-1 who do not meet criteria for GH deficiency. It is honest to describe this as a use supported by plausible physiology and small short-term studies, not by outcome trials. Both the Endocrine Society and the American Association of Clinical Endocrinology hold that GH therapy itself should be reserved for confirmed deficiency and not given for age-related decline, according to Endotext. No major endocrine society guideline recommends GHRH analogs for healthy aging either. Some people and their prescribers decide the modest potential benefit and mild short-term side effect profile justify a monitored trial. That is a personal medical decision, and it should be made with those facts on the table.

Sermorelin is one of several GH-releasing agents. Tesamorelin, a different GHRH analog, has a larger trial base focused on abdominal fat, and ghrelin-receptor drugs work through the second "go" pathway. None of them has been shown to slow aging.

Who should not use either

• Anyone with active cancer. This is a labeled contraindication for somatropin, and the same growth-promoting logic applies to anything that raises GH and IGF-1.
• Anyone who is critically ill, such as after major surgery or trauma.
• People with active proliferative or severe non-proliferative diabetic retinopathy (a labeled somatropin contraindication).
• Anyone who is pregnant or breastfeeding, since neither drug has been studied for wellness use in pregnancy.
• Adolescents, outside of care by a pediatric endocrinologist.
• Competitive athletes subject to drug testing.

People with diabetes or prediabetes, untreated thyroid disease, a history of cancer, or a known pituitary tumor need an individualized discussion with a physician who knows their history before considering either drug.

Myths and realities

Myth: sermorelin is natural HGH

Sermorelin contains no growth hormone. It is a synthetic signal peptide. The GH it releases is your own, and the amount is limited by what your pituitary can make and by feedback.

Myth: sermorelin gives you the results of HGH without the risks

The best HGH trials in healthy older adults showed about 2 kg of fat loss and no gain in strength, with frequent side effects. Sermorelin's measured effects are smaller than that, and its side effects appear milder. Smaller effect and smaller risk travel together. No trial has compared the two in adults.

Myth: sermorelin is FDA approved

It was. Geref was discontinued in 2008, its approval was withdrawn in 2009, and no approved sermorelin product exists in the US as of September 2026. Whether it comes from a compounding pharmacy or a third-party-tested peptide supplier, the sermorelin available today has not been reviewed by the FDA for safety, effectiveness, or quality.

Myth: a doctor can prescribe HGH for anti-aging if they think it will help

Not lawfully. Federal law restricts HGH distribution to authorized medical conditions, and the FDA states that no anti-aging, bodybuilding, or athletic use has been authorized.

Myth: restoring youthful growth hormone levels is proven to slow aging

GH and IGF-1 fall with age, and raising them shifts body composition a little. No human trial of HGH or any GHRH analog has shown a reduction in age-related disease or a longer life. Endotext concludes that until long-term studies with hard clinical endpoints are done, no firm statement about the merits of treatment can be made.

Myth: sermorelin is proven to improve sleep

GH pulses are tied to deep sleep, which is why bedtime dosing is used. But in the 16 week Khorram trial of a close sermorelin analog, sleep quality did not change in men or women, and Endotext notes that most GH and GHRH studies in older adults did not improve slow wave sleep.

Questions to ask your prescriber

1. What diagnosis or goal are you treating, and has true growth hormone deficiency been considered or ruled out?
2. What is my baseline IGF-1 compared with the reference range for my age, and what level would make you lower the dose or stop?
3. Where does the sermorelin come from: a compounding pharmacy, an outsourcing facility, or a peptide supplier? Is each batch tested by an independent laboratory for identity, purity, and sterility, and can I see the certificate of analysis?
4. How will you monitor my blood sugar and thyroid function while I am on it?
5. What specific change should I expect, by when, and what will we do if my IGF-1 and symptoms have not changed by then?
6. Given my personal and family cancer history, is raising GH and IGF-1 appropriate for me?
7. Are you combining sermorelin with other peptides, and what human evidence supports that combination?
8. What proven measures, such as resistance training, adequate protein, sleep, and reducing abdominal fat, should I have in place first?

That last question matters more than it may seem. Exercise, sleep, food intake, stress, and body composition all influence GH secretion, and Endotext describes resistance training as the most effective intervention for increasing muscle mass and strength in older adults, the very outcome GH drugs have failed to move in trials. Hormone therapy of any kind works best as one part of a broader plan for healthy aging, not as a stand-in for it.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.